SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Stock Attack II - A Complete Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Paul Shread who wrote (41047)11/20/2002 8:41:18 PM
From: Compadre  Read Replies (1) | Respond to of 52237
 
Are you talking about the NDX?



To: Paul Shread who wrote (41047)11/20/2002 8:45:59 PM
From: Casaubon  Read Replies (1) | Respond to of 52237
 
hey man, you don't have to bottom tick them to make money. Let's have everyones best ideas out on the table.

stockcharts.com[h,a]daclyyay[pa8.6!d20,2][vc60][iUg!Ll14]&pref=G

EGFR humanized monoclonal antibodies (MAB) vs. some solid tumors. This class of molecules got a lot of bad press because of the astra zeneca poor clinical result with Iressa (targets EGFR with a small molecule, not a MAB)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News